血清sCD44std变化与卵巢癌的初步研究  

Clinical study on serum soluble sCD44std in human ovarian carcinoma

作　　者：林晓[1] 徐军[1] 陆杲川[1] 石礼红[1] 孙蕾[1] 皱文燕 

机构地区：[1]上海市第八人民医院妇产科,上海200233

出　　处：《世界肿瘤杂志》2005年第3期189-190,195,共3页Tumour Journal of the World

基　　金：上海市卫生局科研基金资助项目（编号：00403）

摘　　要：目的 探讨卵巢癌病人血清可溶性CD44标准型（sCD44std）的表达水平及其临床意义。方法 应用定量酶联免疫吸附法（ELISA），检测31例卵巢癌病人血清sCD44std水平。结果 卵巢癌病人血清sCD44std的水平明显高于良性卵巢肿瘤病人及正常人，手术后血清sCD44std明显下降；sCD44std水平与卵巢癌FIGO分期有关，而与卵巢癌的病理类型及细胞分化无关。结论 血清sCD44std可作为卵巢癌辅助诊断及病情估计的一个重要的分子生物学指标。Objective To determine the serum soluble CD44std in human ovarian carcinoma and analyze its clinical significance. Methods The level of serum sCD44std was measured by ELISA kit. Results The level of serum sCD44std in ovarian carcinoma was significantly higher than that of normal control and benign ovarian tumors, and decreased significantly after operation. The levels of serum sCD44std in ovarian carcinoma correlated with the FIGO stage,but not correlate with pathologic type and tumour grade. Conclusion The level of serum sCD44std may served as an important molecular-biological indicator for diagnosis and assessment in ovarian carcinoma.

关 键 词：卵巢肿瘤 血清 可溶性CD44标准型 

分 类 号：R737.31[医药卫生—肿瘤] R-33[医药卫生—临床医学]